Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Targeting properties of an anti-CD16/anti-CD30 bispecific: antibody in an in vivo system
Autore:
Renner, C; Stehle, I; Lee, FT; Hall, C; Catimel, B; Nice, EC; Mountain, A; Rigopoulos, A; Brechbiel, MW; Pfreundschuh, M; Scott, AM;
Indirizzi:
Univ Saarland, Med Dept 1, D-66424 Homburg, Germany Univ Saarland Homburg Germany D-66424 d Dept 1, D-66424 Homburg, Germany Austin & Repatriat Med Ctr, Ludwig Inst Canc Res, Heidelberg, Vic, Australia Austin & Repatriat Med Ctr Heidelberg Vic Australia berg, Vic, Australia NCI, Radioimmune & Inorgan Chem Sect, ROB, DCS,NIH, Bethesda, MD 20892 USANCI Bethesda MD USA 20892 Chem Sect, ROB, DCS,NIH, Bethesda, MD 20892 USA
Titolo Testata:
CANCER IMMUNOLOGY IMMUNOTHERAPY
fascicolo: 2, volume: 50, anno: 2001,
pagine: 102 - 108
SICI:
0340-7004(200104)50:2<102:TPOAAB>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
REFRACTORY HODGKINS-DISEASE; BINDING-SITE BARRIER; CELLS IN-VITRO; HUMAN T-CELLS; MONOCLONAL-ANTIBODIES; TUMORS; THERAPY; CANCER; LYSIS; FRAGMENTS;
Keywords:
bispecific antibodies; Hodgkin's lymphoma; tumor targeting;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Renner, C Univ Saarland, Med Dept 1, Kirrberger Str, D-66424 Homburg, Germany Univ Saarland Kirrberger Str Homburg Germany D-66424 g, Germany
Citazione:
C. Renner et al., "Targeting properties of an anti-CD16/anti-CD30 bispecific: antibody in an in vivo system", CANCER IMMU, 50(2), 2001, pp. 102-108

Abstract

Bispecific antibodies are currently being used in clinical trials in increasing numbers in the areas of breast cancer, prostate cancer, non-Hodgkin'slymphoma and Hodgkin's lymphoma. We have previously performed two clinicaltrials in patients with Hodgkin's disease with an anti-CD30/anti-CD16 bispecific anti body and demonstrated a 30% response rate in a cohort of patients otherwise resistant to standard therapeutic modalities. However, no surrogate marker could be defined in these trials indicative of optimal antibody dosing/scheduling or predictive for favorable response. In order to evaluate accurately the potential biodistribution properties of bispecific antibody in patients, we have performed a detailed analysis of the binding properties and animal model in vivo characteristics of these constructs. For this purpose, the parental antibodies (anti-CD30 and anti-CD16) and the bispecific antibody (anti-CD30/anti-CD16) were radiolabeled with either I-125 or In-111. Antibody integrity and binding properties after labeling were confirmed by Scatchard plot and Lindmo analysis. In-111-labeled antibodies revealed superior targeting properties in a standard SCID mouse tumor model. Both the bivalent parental anti-CD30 monoclonal antibody and the monovalent anti-CD30/ anti-CD16 bispecific antibody showed excellent uptake in CD30(+) tumors which did not differ significantly between the two (maximum uptake 16.5% +/- 4.2% vs. 18.4% +/- 3.8% injected dose/gram tissue). The equivalent targeting properties of the bispecific antibody compared with the parental anti-CD30 antibody encourages the further clinical development of this bispecific antibody, and might help to explain the clinical responses seen withthis antibody so far in patients suffering from Hodgkin's disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 15:55:29